Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics

ACS Medicinal Chemistry Letters

Volumn 4, Issue 7, 2013, Pages 627-631

  Jin, Meizhong ^a   Petronella, Brenda A ^a   Cooke, Andy ^a   Kadalbajoo, Mridula ^a   Siu, Kam W ^a   Kleinberg, Andrew ^a   May, Earl W ^a   Gokhale, Prafulla C ^a   Schulz, Ryan ^a   Kahler, Jennifer ^a   Bittner, Mark A ^a   Foreman, Kenneth ^a   Pachter, Jonathan A ^a   Wild, Robert ^a   Epstein, David ^a   Mulvihill, Mark J ^a  

^a OSI PHARMACEUTICALS INC   (United States)

Author keywords

cancer; Insulin like growth factor 1 receptor (IGF 1R); slow off rate; time dependent inhibition

Indexed keywords

LINSITINIB; PYRAZINE DERIVATIVE; SOMATOMEDIN C RECEPTOR;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER INHIBITION; COLON CANCER; DRUG EFFICACY; DRUG HALF LIFE; ENZYME ACTIVITY; HUMAN; IC 50; PRIORITY JOURNAL; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; XENOGRAFT;

EID: 84880148746     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400160a     Document Type: Article

References (17)

1. Kaiser, U.; Schardt, C.; Brandscheidt, D.; Wollmer, E.; Havemann, K. Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer J. Cancer Res. Clin. Oncol. 1993, 119, 665-668
2. Kondo, M.; Suzuki, H.; Ueda, R.; Osada, H.; Takagi, K.; Takahashi, T.; Takahashi, T. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers Oncogene 1995, 10, 1193-1198
3. Rubin, R.; Baserga, R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity Lab. Invest. 1995, 73, 311-331
4. LeRoith, D.; Roberts, C. T., Jr. The insulin-like growth factor system and cancer Cancer Lett. 2003, 195, 127-137
5. Ma, J.; Giovannucci, E.; Pollak, M.; Leavitt, A.; Tao, Y.; Gaziano, J. M.; Stampfer, M. J. A prospective study of plasma C-peptide and colorectal cancer risk in men J. Natl. Cancer Inst. 2004, 96, 546-553
6. Jin, M.; Wang, J.; Buck, L.; Mulvihill, M. Small molecule ATP-competitive dual IGF-1R and IR inhibitors: Structural insights, chemical diversity and molecular evolution Future Med. Chem. 2012, 4, 315-328
7. Li, R.; Pourpak, A.; Morris, S. W. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach J. Med. Chem. 2009, 52, 4981-5004
8. Lu, H.; Tonge, P. J. Drug-target residence time: critical information for lead optimization Curr. Opin. Chem. Biol. 2010, 14, 467-474
9. Zhang, R.; Monsma, F. The importance of drug-target residence time Curr. Opin. Drug Discovery Dev. 2009, 12, 488-496
10. Copeland, R. A. Conformational adaptation in drug-target interactions and residence time Future Med. Chem. 2011, 3, 1491-1501
11. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 2006, 5, 730-739
12. Ji, Q.; Mulvihill, M.; Rosenfeld-Franklin, M.; Cooke, A.; Feng, L.; Mak, G.; O'Connor, M.; Yao, Y.; Pirritt, C.; Buck, E.; Eyzaguirre, A.; Arnold, L.; Gibson, N.; Pachter, J. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo Mol. Cancer Ther. 2007, 6, 2158-2167
13. Mulvihill, M.; Ji, Q.; Coate, H.; Cooke, A.; Dong, H.; Feng, L.; Foreman, K.; Rosenfeld-Franklin, M.; Honda, A.; Mak, G.; Mulvihill, K.; Nigro, A.; O'Connor, M.; Pirrit, C.; Steinig, A.; Siu, K.; Stolz, K.; Sun, Y.; Tavares, P.; Yao, Y.; Gibson, N. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5- a ]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors Bioorg. Med. Chem. 2008, 16, 1359-1375
14. Mulvihill, M.; Cooke, A.; Rosenfeld-Franklin, M.; Buck, E.; Foreman, K.; Landfair, D.; O'Connor, M.; Pirrit, C.; Sun, Y.; Yao, Y.; Arnold, L.; Gibson, N.; Ji, Q. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor Future Med. Chem. 2009, 1, 1153-1171
15. Jin, M.; Kleinberg, A.; Cooke, A.; Gokhale, P. C.; Foreman, K.; Dong, H.; Siu, K. W.; Bittner, M. A.; Mulvihill, K. M.; Yao, Y.; Landfair, D.; O'Connor, M.; Mak, G.; Pachter, J. A.; Wild, R.; Rosenfeld-Franklin, M.; Ji, Q.; Mulvihill, M. J. Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy Bioorg. Med. Chem. Lett. 2011, 21, 1176-1180
16. Jin, M.; Gokhale, P.; Cooke, A.; Foreman, K.; Buck, E.; May, E.; Feng, L.; Bittner, M.; Kadalbajoo, M.; Landfair, D.; Siu, K.; Stolz, K.; Werner, D.; Laufer, R.; Li, A.; Dong, H.; Steinig, A.; Kleinberg, A.; Yao, Y.; Pachter, J.; Wild, R.; Mulvihill, M. J. Discovery of an orally efficacious imidazo[5,1- f ][1,2,4]triazine dual inhibitor of IGF-1R and IR ACS Med. Chem. Lett. 2010, 1, 510-515
17. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890